Subscribe

  • How Can We Help You?

    Global Problem Solving from Covington: Deal with Complex Problems Anywhere in the World

Covington Advises GSK on 23andMe Collaboration and $300M Investment

Press Release July 30, 2018

  • News and Insights
  • Covington Advises GSK on 23andMe Collaboration and 300M Investment

Covington Advises GSK on 23andMe Collaboration and $300M Investment

July 30, 2018

SILICON VALLEY—Covington advised GlaxoSmithKline on its multi-year collaboration with and $300 million equity investment in 23andMe.

GSK will become 23andMe’s exclusive collaborator for drug target discovery programs. The collaboration will focus on research and development of innovative new medicines and potential cures using human genetics as the basis for discovery.

The Covington team included Scott Anthony, Peter Laveran-Stiebar, Amy Toro, Anqi Li, David Wildman, and Mengxi Zhu (corporate); Yaron Dori and Dena Feldman (privacy); Wade Ackerman, Lynette Zentgraft, and Christopher Hanson (U.S. regulatory); Grant Castle and Sarah Cowlishaw (EU regulatory); Miranda Cole, James O’Connell, Ross Demain, and Habin Chung (antitrust and competition); Christopher Eppich and Andrew Regan (intellectual property); Peter Flanagan, David Addis, and Molly Doggett (U.S. export control); Richard Mattick (EU export control); and Scott Freling and Nooree Lee (government contracts).

Related Professionals

Share links:

Share links:

Related Practices

Related Industries

Related Offices

Related Regions

Related News & Insights